RAXIBACUMAB
PeakmAbBLAIV (INFUSION)INJECTABLEPriority Review
Approved
Dec 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Raxibacumab is a monoclonal antibody directed against anthrax protective antigen (PA), the key virulence factor of Bacillus anthracis. It is indicated for inhalation anthrax in combination with standard antibiotic therapy, working by neutralizing PA and preventing cellular entry of anthrax toxins. This is a specialized biodefense therapeutic for a rare but serious infectious disease.
Peak
Niche biodefense product with stable but limited commercial footprint; smaller team structure focused on government contracts and emergency preparedness.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax
Started May 2027
10 enrolled
Infections, Bacterial
Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario
Started Jan 2027
100 enrolled
Infections, Bacterial
Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed
Started Feb 2015
573 enrolled
Infections, Bacterial
A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects
Started Mar 2008
322 enrolled
Healthy
An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection
Started Jan 2008
20 enrolled
Therapeutic Treatment of Inhalation Anthrax
Worked on RAXIBACUMAB at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.